Eli Lilly and Co (NYSE:LLY) stock is trading higher after the company released better-than-expected fourth-quarter earnings ...

There are no studies documenting the percentage of doctors taking the drugs. But physicians “are a good litmus test for drugs that are highly effective,” Dr. Califf said. If doctors who read the ...

"It's frankly scary what people will put up with when they're losing weight" Dr Michael Crotty on the rollout of Mounjaro ...

TikTok is full of wellness and health trends, and a leading doctor has shared his thoughts on the new 'Mounjaro drink' people ...

Eli Lilly & Co. said its Type-2 Diabetes drug Mounjaro and weight-loss/diabetes medicine Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion.

New rules will make it harder to get weight loss jabs online, but what will happen to obese people desperate for help? Two ...

Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of ...

WVU Medicine is playing a lead role in a national clinical study of a minimally invasive surgical procedure for people who've ...

STRUGGLING to keep up with her two young children and dreading her own reflection in the mirror, Emma Lasenby knew something ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion. The drugmaker ...

Eli Lilly reported mixed fourth-quarter results on Thursday, surpassing earnings expectations but falling short of sales projections, even as demand for its flagship weight loss drug Zepbound and ...